We serve L-Lysine Acetate CAS:57282-49-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
L-Lysine Acetate
An acetate salt of L-lysine. L-Lysine is an essential amino acid in human. It is metabolized to acetyl-CoA. It is widely used as an ingredient in infusion.
| Cas.No | 57282-49-2 |
| Assay | 99.0-101.0% |
| Specification | White crystals or crystalline powder, characteristic odor, slightly acid taste |
| Applications | Infusion |
| Packaging | 25kg&50kg |
| Pharmacopeia | JP,USP,EP |
| STORAGE | Controlled room temperature in tight container |
SPECIFICATION AND PROCEDURE
| State of solution (Transmittance) |
Not Less Than 98.0% |
| pH | 6.5～7.5 |
| Specific rotation[α]20D | +8.5～+10.0° |
| Specific rotation[α]25D | +8.4～+9.9° |
| Ammonium (NH4) | Not More Than 0.020% |
| Chloride (Cl) | Not More Than 0.020% |
| Sulfate (SO4) | Not More Than 0.020% |
| Iron (Fe) | Not More Than 10 ppm |
| Heavy metals (Pb)** | Not More Than 10 ppm |
| Arsenic (As2O3) | Not More Than 1 ppm |
| Loss on drying | Not More Than 0.20% |
| Residue on ignition | Not More Than 0.10% |
| Related substances | Not More Than 0.1% |
| Endotoxin* | Less Than 6.0 EU/g |
| Assay (dry basis) | 99.0～101.0% |
· * The endotoxin-certified grade will be supplied on request.
· This product meets requirements of residual solvents listed in the current JP, USP and EP.
Contact us for information like L-Lysine Acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-LYS AC physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L-LYS AC Use and application,Lysine acetate salt technical grade,usp/ep/jp grade.
Related News: This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.2-fluoro-5-[(Z)-(3-oxo-2-benzofuran-1-ylidene)methyl]benzonitrile manufacturer This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.Tetra-(methylethylketoxime)silane supplier In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.2-Amino-4,6-dimethylpyrimidine vendor Professor Coleman was involved in some of the first research into MERS in the US.This is how an API becomes a medicine.
